Page 89 - Read Online

Michaelis et al. Cancer Drug Resist 2019;2:447-56 I http://dx.doi.org/10.20517/cdr.2019.005 Page 453

4. Litwin MS, Tan HJ. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA 2017;317:2532-42.
5. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018;553:446-54.
6. Lim SH, Johnson PWM. Optimizing therapy in advanced-stage Hodgkin lymphoma. Blood 2018;131:1679-88.
7. Pierorazio PM, Albers P, Black PC, Tandstad T, Heidenreich A, et al. Non-risk-adapted Surveillance for Stage I Testicular Cancer: Critical
Review and Summary. Eur Urol 2018;73:899-907.
8. Fenton TR, Garrett MD, Wass MN, Michaelis M. What really matters - response and resistance in cancer therapy. Cancer Drug Resist
2018;1:200-3.
9. DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res 2008;68:8643-53.
10. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer
2013;13:714-26.
11. Sachs JR, Mayawala K, Gadamsetty S, Kang SP, de Alwis DP. Optimal Dosing for Targeted Therapies in Oncology: Drug Development
Cases Leading by Example. Clin Cancer Res 2016;22:1318-24.
12. Wong KM, Capasso A, Eckhardt SG. The changing landscape of phase I trials in oncology. Nat Rev Clin Oncol 2016;13:106-17.
13. Gatzka MV. Targeted Tumor Therapy Remixed-An Update on the Use of Small-Molecule Drugs in Combination Therapies. Cancers
(Basel) 2018;10:pii:E155.
14. Kavanagh S, Nee A, Lipton JH. Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia. Expert Opin
Emerg Drugs 2018;23:51-62.
15. Kleczko EK, Heasley LE. Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and
inherent therapeutic vulnerabilities. Mol Cancer 2018;17:60.
16. Larionov AA. Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. Front
Oncol 2018;8:89.
17. Sharma GG, Mota I, Mologni L, Patrucco E, Gambacorti-Passerini C, et al. Tumor Resistance against ALK Targeted Therapy-Where It
Comes From and Where It Goes. Cancers (Basel) 2018;10:pii:E62.
18. Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase
signaling and counteracting resistance for successful cancer therapy. Mol Cancer 2018;17:49.
19. Tomasello C, Baldessari C, Napolitano M, Orsi G, Grizzi G, et al. Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical
management and future perspectives. Crit Rev Oncol Hematol 2018;123:149-61.
20. Esposito C, Rachiglio AM, La Porta ML, Sacco A, Roma C, et al. The S492R EGFR ectodomain mutation is never detected in KRAS
wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biol Ther 2013;14:1143-6.
21. Arena S, Bellosillo B, Siravegna G, Martínez A, Cañadas I, et al. Emergence of Multiple EGFR Extracellular Mutations during
Cetuximab Treatment in Colorectal Cancer. Clin Cancer Res 2015;21:2157-66.
22. Miklos W, Pelivan K, Kowol CR, Pirker C, Dornetshuber-Fleiss R, et al. Triapine-mediated ABCB1 induction via PKC induces
widespread therapy unresponsiveness but is not underlying acquired triapine resistance. Cancer Lett 2015;361:112-20.
23. Carter L, Rothwell DG, Mesquita B, Smowton C, Leong HS, et al. Molecular analysis of circulating tumor cells identifies distinct copy-
number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nat Med 2017;23:114-9.
24. Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat
Rev Genet 2019;20:71-88.
25. Hayes DF. Precision Medicine and Testing for Tumor Biomarkers-Are All Tests Born Equal? JAMA Oncol 2018;4:773-4.
26. Warren JD, Xiong W, Bunker AM, Vaughn CP, Furtado LV, et al. Septin 9 methylated DNA is a sensitive and specific blood test for
colorectal cancer. BMC Med 2011;9:133.
27. Leighl NB, Rekhtman N, Biermann WA, Huang J, Mino-Kenudson M, et al. Molecular testing for selection of patients with lung cancer
for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology
endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular
pathology guideline. J Clin Oncol 2014;32:3673-9.
28. Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O’Connell A, et al. Prospective Validation of Rapid Plasma Genotyping for the
Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol 2016;2:1014-22.
29. Lee DH. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures. Pharmacol Ther
2017;174:1-21.
30. Nian J, Sun X, Ming S, Yan C, Ma Y, et al. Diagnostic Accuracy of Methylated SEPT9 for Blood-based Colorectal Cancer Detection: A
Systematic Review and Meta-Analysis. Clin Transl Gastroenterol. 2017;8:e216.
31. Song L, Jia J, Peng X, Xiao W, Li Y. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening
tests: A meta-analysis. Sci Rep 2017;7:3032.
32. Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, et al. Molecular Testing Guideline for the Selection of Patients
With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the
College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical
Practice Guideline Update. J Clin Oncol 2018;36:911-9.
33. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev
Cancer 2010;10:241-53.
34. Gordon JL, Brown MA, Reynolds MM. Cell-Based Methods for Determination of Efficacy for Candidate Therapeutics in the Clinical
Management of Cancer. Diseases. 2018;6: pii:E85.